Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Euh Lim Oh

Se Chang Kwon

Sung Youb Jung

Chang Ki Lim

Young Jin Park

Jin Young Kim

Jong Suk Lee

Jong Soo Lee

In Young Choi

Hyung Kyu Lim

Sang Yun Kim

Yong Ho Huh

Yong Ho Heo

Hyun Soo Ryu

Jun Sub Park

Cho Rong Park

Hyun Uk Kim

Sung Hee Park

Min Young Kim

Sang Youn Hwang

A Ram Lee

Jin-Sun Kim

Yu Yon Kim

Da Hyeon Park

Modifications to interleukin-2 alpha receptors are disclosed. Interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors are disclosed.

Immunostimulating IL-2 analogs

The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.

A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Triple glucagon/GLP-1/GIP receptor agonist

A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist

An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.

Insulin analogs and use thereof

The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.

Long-acting insulin and use thereof

Insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described.

The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment intosp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use ofor animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.

Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same

Disclosed is a method of culturingcells for high density, comprising a cell growth step and an expression induction step by which a maximum of cell mass can be obtained with the concomitant maximum expression of a recombinant protein.transformed to produce a recombinant protein of interest can be grown at a high concentration using the culturing method of the present invention. Therefore, the method increases the productivity of cells as well as the production yield of the recombinant protein, and can be widely applied to the effective production of recombinant proteins.

Growing community of inventors

Hwaseong-si, South Korea

Euh Lim Oh